|
1
|
Characterization of clonogenic multiple myeloma cells.
|
Blood
|
2003
|
5.35
|
|
2
|
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
|
Cancer Res
|
2006
|
4.15
|
|
3
|
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
|
Cancer Res
|
2008
|
3.57
|
|
4
|
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
|
Blood
|
2002
|
2.76
|
|
5
|
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
|
Blood
|
2011
|
2.66
|
|
6
|
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.
|
Blood
|
2012
|
2.65
|
|
7
|
High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up.
|
Blood
|
2009
|
2.25
|
|
8
|
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2009
|
2.25
|
|
9
|
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
|
Blood
|
2006
|
2.18
|
|
10
|
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
|
Blood
|
2011
|
2.14
|
|
11
|
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.
|
Blood
|
2004
|
2.03
|
|
12
|
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.
|
Blood
|
2010
|
1.99
|
|
13
|
Acute myeloid leukemia.
|
J Natl Compr Canc Netw
|
2012
|
1.96
|
|
14
|
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
|
Leuk Res
|
2009
|
1.92
|
|
15
|
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.
|
J Mol Diagn
|
2003
|
1.82
|
|
16
|
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
|
Blood
|
2008
|
1.81
|
|
17
|
Cancer stem cells: are we missing the target?
|
J Natl Cancer Inst
|
2004
|
1.72
|
|
18
|
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.
|
Cancer Res
|
2009
|
1.71
|
|
19
|
The paradox of response and survival in cancer therapeutics.
|
Blood
|
2005
|
1.63
|
|
20
|
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.
|
Leuk Lymphoma
|
2012
|
1.57
|
|
21
|
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
|
Blood
|
2011
|
1.56
|
|
22
|
Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
|
J Biol Chem
|
2007
|
1.51
|
|
23
|
Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia.
|
Blood
|
2005
|
1.48
|
|
24
|
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2006
|
1.47
|
|
25
|
Concise review: Emerging concepts in clinical targeting of cancer stem cells.
|
Stem Cells
|
2011
|
1.45
|
|
26
|
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.
|
Leuk Res
|
2008
|
1.43
|
|
27
|
Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.
|
Br J Haematol
|
2005
|
1.41
|
|
28
|
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
|
Blood
|
2005
|
1.38
|
|
29
|
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
|
Blood
|
2011
|
1.36
|
|
30
|
Acute myeloid leukemia, version 2.2013.
|
J Natl Compr Canc Netw
|
2013
|
1.26
|
|
31
|
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients.
|
Invest New Drugs
|
2011
|
1.25
|
|
32
|
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
|
Clin Cancer Res
|
2007
|
1.23
|
|
33
|
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
|
Clin Cancer Res
|
2005
|
1.23
|
|
34
|
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
|
Blood
|
2012
|
1.21
|
|
35
|
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.
|
Blood
|
2011
|
1.20
|
|
36
|
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
|
Clin Cancer Res
|
2012
|
1.20
|
|
37
|
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.
|
Blood
|
2007
|
1.19
|
|
38
|
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.
|
Blood
|
2005
|
1.18
|
|
39
|
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.18
|
|
40
|
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.
|
Biol Blood Marrow Transplant
|
2011
|
1.17
|
|
41
|
Characterization of chronic myeloid leukemia stem cells.
|
Am J Hematol
|
2011
|
1.15
|
|
42
|
Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation.
|
Leuk Lymphoma
|
2010
|
1.13
|
|
43
|
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.
|
Cancer Res
|
2009
|
1.09
|
|
44
|
Acute myeloid leukemia.
|
J Natl Compr Canc Netw
|
2011
|
1.09
|
|
45
|
Chronic Myelogenous Leukemia, Version 1.2014.
|
J Natl Compr Canc Netw
|
2013
|
1.07
|
|
46
|
Strategies to eliminate cancer stem cells: clinical implications.
|
Eur J Cancer
|
2006
|
1.02
|
|
47
|
Chronic myelogenous leukemia, version 1.2015.
|
J Natl Compr Canc Netw
|
2014
|
1.02
|
|
48
|
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.
|
Clin Cancer Res
|
2012
|
1.01
|
|
49
|
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
|
Biol Blood Marrow Transplant
|
2006
|
0.99
|
|
50
|
Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
|
Clin Ther
|
2010
|
0.98
|
|
51
|
Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS).
|
Am J Med
|
2013
|
0.96
|
|
52
|
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
|
Clin Cancer Res
|
2008
|
0.93
|
|
53
|
CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak.
|
J Biol Chem
|
2013
|
0.93
|
|
54
|
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
|
Haematologica
|
2011
|
0.92
|
|
55
|
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.
|
Blood
|
2010
|
0.92
|
|
56
|
The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo.
|
Cancer Res
|
2005
|
0.92
|
|
57
|
High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.
|
Biol Blood Marrow Transplant
|
2005
|
0.91
|
|
58
|
Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.
|
Epigenetics
|
2010
|
0.91
|
|
59
|
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
|
Haematologica
|
2012
|
0.90
|
|
60
|
Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation.
|
Br J Haematol
|
2003
|
0.89
|
|
61
|
Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.
|
Curr Opin Oncol
|
2004
|
0.89
|
|
62
|
Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.
|
J Biol Chem
|
2009
|
0.88
|
|
63
|
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2011
|
0.88
|
|
64
|
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.
|
Am J Hematol
|
2014
|
0.87
|
|
65
|
Acute myeloid leukemia clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.87
|
|
66
|
Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.
|
Br J Haematol
|
2005
|
0.87
|
|
67
|
The role of growth factors in the activity of pharmacological differentiation agents.
|
Cell Growth Differ
|
2002
|
0.87
|
|
68
|
Chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2012
|
0.84
|
|
69
|
Are results of targeted gene sequencing ready to be used for clinical decision making for patients with acute myelogenous leukemia?
|
Curr Hematol Malig Rep
|
2013
|
0.83
|
|
70
|
Osteoblasts protect AML cells from SDF-1-induced apoptosis.
|
J Cell Biochem
|
2014
|
0.82
|
|
71
|
Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
|
J Natl Cancer Inst
|
2011
|
0.81
|
|
72
|
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.
|
Am J Hematol
|
2005
|
0.81
|
|
73
|
Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression.
|
J Biol Chem
|
2014
|
0.80
|
|
74
|
FLT3 inhibitors in acute myeloid leukemia.
|
Expert Rev Hematol
|
2008
|
0.80
|
|
75
|
A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice.
|
J Mol Diagn
|
2009
|
0.80
|
|
76
|
Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry.
|
Anal Biochem
|
2005
|
0.80
|
|
77
|
NCCN task force report: molecular markers in leukemias and lymphomas.
|
J Natl Compr Canc Netw
|
2009
|
0.79
|
|
78
|
Chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2007
|
0.78
|
|
79
|
New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation.
|
Clin Adv Hematol Oncol
|
2005
|
0.78
|
|
80
|
Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia.
|
Am J Med Sci
|
2011
|
0.77
|
|
81
|
Acute myeloid leukemia.
|
J Natl Compr Canc Netw
|
2008
|
0.77
|
|
82
|
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
|
Haematologica
|
2013
|
0.77
|
|
83
|
The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?
|
Leuk Lymphoma
|
2014
|
0.75
|
|
84
|
Response to 'comparison of "sequential" versus "standard" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial'.
|
Br J Haematol
|
2003
|
0.75
|
|
85
|
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
|
Br J Haematol
|
2012
|
0.75
|
|
86
|
Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
|
Leuk Res
|
2011
|
0.75
|
|
87
|
Exploiting oxidative damage to overcome resistance.
|
Leuk Res
|
2006
|
0.75
|
|
88
|
Chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2005
|
0.75
|
|
89
|
Trying to improve clinical outcome in AML: lessons from negative trials.
|
Leuk Res
|
2005
|
0.75
|
|
90
|
Developmental clinical trials: building one step at a time.
|
Leuk Res
|
2006
|
0.75
|